Abbott Laboratories (NYSE:ABT) was up 1.29% at $91.70 as of the latest intraday update on Wednesday, rebounding toward a one-month high as institutional money rotated into healthcare and medtech names amid a broader sector recovery.
Key Highlights
- Abbott (NYSE:ABT) was trading near a one-month high at $91.70 as of the latest intraday update, rebounding sharply from its 52-week low of $81.97 set earlier in June.
- The stock remains down roughly 27% year-to-date, trading well below its 200-day moving average of $113.20, signalling recovery is early-stage.
- No company-specific news drove Wednesday's gain; sector rotation away from defensive telecom and energy names provided the primary lift.
- Healthcare and medtech names broadly outperformed as investors redeployed capital from Tuesday's market selloff entry point.
Abbott Laboratories (NYSE:ABT) was up 1.29% at $91.70 as of the latest intraday update on Wednesday and was trading in territory not seen in nearly a month, as healthcare and medtech stocks attracted meaningful rotation interest from investors exiting defensive telecom and energy positions.
The move built on a technical setup created by Tuesday's broader market selloff, which pushed Abbott near its 52-week low of $81.97 set earlier in June and brought fresh buyers into the stock. No company-specific announcement or data release had acted as a catalyst as of the latest intraday update.
Abbott's recovery nonetheless remains in its early stages. The stock continues to trade well below its 200-day moving average of $113.20 and is down approximately 27% since January, reflecting persistent selling pressure that followed first-quarter earnings digestion. Investors have been cautious about the pace of recovery in Abbott's diagnostics segment following a post-pandemic normalisation in testing volumes.
The intraday gain places Abbott within a broader healthcare rebound that drew institutional participation across device and diagnostics names. Sector indices moved higher as market participants reassessed risk positioning after the prior session's sharp losses.
Abbott's proximity to its 52-week low continues to offer a reference point for value-oriented investors monitoring the stock's technical floor, even as the 200-day moving average overhead represents a substantial recovery requirement before the longer-term trend can be considered restored.






Please wait processing your request...